Vanda Pharmaceuticals
Vanda Pharmaceuticals completes enrollment for phase 3 trials on schizophrenia and insomnia
Published in Pharma Law Weekly, September 26th, 2006
The iloperidone clinical trial is a randomized, double-blind, placebo-controlled phase 3 trial in patients with schizophrenia. Vanda concluded enrollment in this trial with 604 patients as of August 29, 2006. The VEC-162 clinical trial is a randomized, double-blind, placebo-controlled transient insomnia trial in healthy volunteers. Vanda concluded enrollment in this trial with 412 patients as of August 21,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2006-09-26)
More Articles from Pharma Law Weekly
- AGA Medical
AGA Medical files suit in Germany alleging patent infringement - Bradley Pharmaceuticals
Bradley Pharmaceuticals announces initiatives to enhance shareholder value - Decision Resources
New drugs will capture share but generic erosion of Fosamax will stymie market - Diomed Holdings
Diomed wins motion on validity and enforceability of EVLT patent, trial on infringement expected - Economic and Social Research Council
Increase in drug development for killer diseases hampered by poverty in developing countries - Emory University, U.S.
Studies from the United States, Belgium and Italy describe new findings in surgery research - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
